Clinical Trials Browser

OTHER × Adenocarcinoma of Lung × trametinib × Clear all

NCT03076164 2024-04-02

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

Phase 1/2 Completed

24 enrolled 8 charts

Adenocarcinoma of Lung, Lung Neoplasms